← Leaderboards
Luis Martinez-Sobrido
University Of Alabama At Birmingham
$6,855,646
Attributed
$12,547,508
Total exposure
13
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2008–24$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,547,508 · 13
By mechanism
R01$8,962,567 · 4
R21$2,960,316 · 7
R56$471,125 · 1
R03$153,500 · 1
Top collaborators
- Juan C. De La Torre9 shared
- James J Kobie7 shared
- Mark R Walter3 shared
- Ekaterina Koroleva2 shared
- Slobodan Paessler2 shared
- Alexei V Tumanov2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Allan J Zajac$14,007,973
- Troy D Randall$33,910,350
- Frances E. Lund$38,753,426
- Ming Luo$16,469,559
- Christopher Garrett Wilson$119,619
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusViralVaccinesInfectionRecombinantsMediatingCellsAntiviral AgentsBasePropertyIn VivoResponsePreventVirus DiseasesArenavirusProductionLymphocytic Choriomeningitis VirusCombatViral Hemorrhagic FeversMutationRibavirinImmunePathogenMorbidity - Disease Rate
Grant awards (32)
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies$841,341
R01 · FY2024 · AI
Novel animal models to study organ-specific SARS-CoV-2-induced pathology$220,625
R21 · FY2024 · AI
Novel animal models to study organ-specific SARS-CoV-2-induced pathology$278,500
R21 · FY2023 · AI
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies$841,228
R01 · FY2022 · AI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$759,187
R01 · FY2022 · AI
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$434,375
R01 · FY2022 · AI
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies$856,430
R01 · FY2021 · AI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$758,319
R01 · FY2021 · AI
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$434,375
R01 · FY2021 · AI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$757,938
R01 · FY2020 · AI
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$434,375
R01 · FY2020 · AI
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response$750,079
R01 · FY2019 · AI
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology$457,750
R01 · FY2019 · AI
Attenuation Of Lassa Virus Via Codon DeoptimizationâÂÂ$147,180
R21 · FY2019 · AI · contact PI
Attenuation of Lassa Virus Via Codon Deoptimization$144,892
R21 · FY2019 · AI · contact PI
Development of Human Broadly Neutralizing Monoclonal Antibodies Against New World Arenavirusesâ$277,659
R21 · FY2018 · AI · contact PI
Attenuation Of Lassa Virus Via Codon Deoptimizationâ$230,063
R21 · FY2018 · AI · contact PI
Single-cycle infectious Zika viruses for the development of a live-attenuated vaccine$199,865
R21 · FY2018 · AI · contact PI
Broadly Neutralizing Antibodies Against Human Pathogenic Old World Arenaviruses$248,106
R21 · FY2017 · AI · contact PI
Development of Human Broadly Neutralizing Monoclonal Antibodies Against New World Arenavirusesâ$217,469
R21 · FY2017 · AI · contact PI
Single-cycle infectious Zika viruses for the development of a live-attenuated vaccine$180,457
R21 · FY2017 · AI · contact PI
Broadly Neutralizing Antibodies Against Human Pathogenic Old World Arenaviruses$222,800
R21 · FY2016 · AI · contact PI
Development of a safe and valid surrogate to study Lassa virus$192,850
R21 · FY2016 · AI
Development of a safe and valid surrogate to study Lassa virus$245,350
R21 · FY2015 · AI
Single-cycle Infectious Candid#1 to Study Hemorrhagic Fever New World Arenavirus$76,750
R03 · FY2013 · AI · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$440,310
R01 · FY2012 · AI
Single-cycle Infectious Candid#1 to Study Hemorrhagic Fever New World Arenavirus$76,750
R03 · FY2012 · AI · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$440,310
R01 · FY2011 · AI
Identification of compounds that activate interferon to treat viral infections$154,500
R21 · FY2011 · NS · contact PI
Anti-interferon Activity of the Arenavirus Nucleoprotein$444,757
R01 · FY2010 · AI
Anti-interferon Activity of the Arenavirus Nucleoprotein$311,793
R01 · FY2009 · AI
Anti-interferon Activity of the Arenavirus Nucleoprotein$471,125
R56 · FY2008 · AI